В. В. Бредер

21.1k total citations · 6 hit papers
108 papers, 3.9k citations indexed

About

В. В. Бредер is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, В. В. Бредер has authored 108 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 55 papers in Hepatology and 44 papers in Pulmonary and Respiratory Medicine. Recurrent topics in В. В. Бредер's work include Hepatocellular Carcinoma Treatment and Prognosis (52 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Lung Cancer Treatments and Mutations (29 papers). В. В. Бредер is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (52 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Lung Cancer Treatments and Mutations (29 papers). В. В. Бредер collaborates with scholars based in Russia, United States and France. В. В. Бредер's co-authors include Masatoshi Kudo, Philippe Merle, Ann‐Lii Cheng, Andrew X. Zhu, Richard S. Finn, Ho Yeong Lim, Stephen L. Chan, Bruno Daniele, Peter R. Galle and Marcelo Garrido and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

В. В. Бредер

82 papers receiving 3.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

2019 1.3k citations Richard S. Finn, Baek‐Yeol Ryoo et al. Journal of Clinical Oncology profile →
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

2021 891 citations Ann‐Lii Cheng, Shukui Qin et al. profile →
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

2022 259 citations Stephen L. Chan, Masatoshi Kudo et al. Journal of Clinical Oncology profile →
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

2021 229 citations Richard S. Finn, Peter R. Galle et al. Journal of Clinical Oncology profile →
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

2021 162 citations Salma K. Jabbour, Ki Hyeong Lee et al. profile →
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial

2024 51 citations В. В. Бредер et al. profile →

Peers

Countries citing papers authored by В. В. Бредер

Since Specialization

Citations

This map shows the geographic impact of В. В. Бредер's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by В. В. Бредер with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites В. В. Бредер more than expected).

Fields of papers citing papers by В. В. Бредер

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by В. В. Бредер. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by В. В. Бредер. The network helps show where В. В. Бредер may publish in the future.

Co-authorship network of co-authors of В. В. Бредер

This figure shows the co-authorship network connecting the top 25 collaborators of В. В. Бредер. A scholar is included among the top collaborators of В. В. Бредер based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with В. В. Бредер. В. В. Бредер is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	166P Outcomes by baseline liver function in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) with or without bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC) 2024 ·Annals of Oncology ·(unknown), Thomas Decaens, (unknown), Joseph P. Erinjeri, Riccardo Lencioni, (unknown), В. В. Бредер, Jeong Heo, Vincenzo Mazzaferro, Jung‐Won Park, (unknown), (unknown), Y. Xu, Yoshitaka Inaba, (unknown), (unknown), Cheryl L. McCoy, (unknown), Bruno Sangro	0
2	127O Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) 2024 ·Annals of Oncology ·Mitsuhiro Kudo, Lorenza Rimassa, (unknown), Bruno Sangro, George Lau, В. В. Бредер, (unknown), Oxana Crysler, (unknown), Tu Van Dao, Adilson Faccio, Junji Furuse, L-B. Jeng, Y-K. Kang, Robin Kate Kelley, Michael J. Paskow, (unknown), Di Ran, Alejandra Negro, (unknown)	1
3	Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma. 2024 ·Journal of Clinical Oncology ·Stephen L. Chan, Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri, Shukui Qin, Zhenggang Ren, Yasuaki Arai, В. В. Бредер, Shi-Ming Lin, Jean‐Marie Péron, Tien Quang Nguyen, Lünan Yan, Chang-Fang Chiu, Florinda Santos, (unknown), Satheesh Chiradoni Thungappa, Claire Morgan, Kerry Parsons, Ioannis Xynos, Riccardo Lencioni	4
4	Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799. 2024 ·Journal of Clinical Oncology ·Martin Reck, Ki Hyeong Lee, Nikolaj Frost, В. В. Бредер, Dariusz M. Kowalski, E. Levchenko, Noemı́ Reguart, Alex Martínez‐Martí, Baerin Houghton, Jean-Baptiste Paoli, (unknown), Liu Hong, (unknown), Elisha J. Dettman, Julie Kobie, Salma K. Jabbour	3
5	Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150 2024 ·Liver Cancer ·Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann‐Lii Cheng, Norelle R. Reilly, Alan Nicholas, Sairy Hernandez, (unknown), Philippe Merle, Riad Salem, Daneng Li, В. В. Бредер	12
6	Злокачественные опухоли печени и желчевыводящей системы 2023 ·Malignant tumours ·В. В. Бредер, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Fedor Moiseenko, (unknown), (unknown), И. А. Покатаев	1
7	Atezolizumab and bevacizumab in the treatment of advanced hepatocellular cancer with adverse factors and tumor thrombosis 2023 ·Meditsinskiy sovet = Medical Council ·(unknown), (unknown), В. В. Бредер, (unknown), (unknown), (unknown), (unknown), (unknown)	0
8	Cirrhosis of the liver and hepatocellular carcinoma in the outcome of chronic hepatitis C: a case report 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), В. В. Бредер, (unknown), (unknown), (unknown)	0
9	Overall survival of patients with liver cirrhosis 2023 ·Medical news of the North Caucasus ·(unknown), (unknown), В. В. Бредер, (unknown)	0
10	Immunotherapy for hepatocellular carcinoma in liver transplant patients (Literature review) 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), В. В. Бредер, (unknown)	0
11	Second line drug therapy for biliary cancer 2022 ·Meditsinskiy sovet = Medical Council ·(unknown), В. В. Бредер, И. С. Стилиди, К. К. Лактионов, (unknown), (unknown), (unknown)	0
12	Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping 2021 ·SHILAP Revista de lepidopterología ·(unknown), В. В. Бредер, Maxim Ivanov, (unknown), (unknown), К. К. Лактионов, (unknown)	0
13	Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC 2021 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), В. В. Бредер	0
14	Intermediate Stage Hepatocellular Carcinoma Classifications: the Review 2021 ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), В. В. Бредер, (unknown)	0
15	Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors 2020 ·SHILAP Revista de lepidopterología ·(unknown), К. К. Лактионов, (unknown), (unknown), В. В. Бредер, (unknown), (unknown), (unknown), (unknown)	2
16	Systemic therapy of hepatocellular carcinoma: reality and prospects 2020 ·Annaly khirurgicheskoy gepatologii = Annals of HPB surgery ·В. В. Бредер, (unknown), (unknown)	0
17	Firsthand experience of chemoradiotherapy in patients with localized small cell lung cancer. Retrospective assessment 2020 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), В. В. Бредер, (unknown), (unknown), К. К. Лактионов	0
18	Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240 2020 ·Cancer ·Baek‐Yeol Ryoo, Philippe Merle, Amit S. Kulkarni, Ann‐Lii Cheng, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Bruno Daniele, Josephine M. Norquist, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Richard S. Finn, Masatoshi Kudo	25
19	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial breakdown → 2019 ·Journal of Clinical Oncology ·Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng, (unknown)	1300
20	Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study 2019 ·Clinical Cancer Research ·Nicholas Thatcher, Jerome H. Goldschmidt, Michael Thomas, Michael Schenker, Zhiying Pan, Luis Paz-Ares Rodríguez, В. В. Бредер, Gyula Ostoros, Vladimir Hanes	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact